Terns Pharmaceuticals, Inc.
TERN
株式のランク
#3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
株価
$52.95
最終同期: 2026-05-15
時価総額
$4.77B
変化（1日）
0.00%
変化（1年）
552.09%
国
US
取引 Terns Pharmaceuticals, Inc. (TERN)
カテゴリー
Healthcare
Terns Pharmaceuticals, Inc.（TERN）の株価履歴
終値の最高値: $52.95 （2026-05-01）
終値の最安値: $20.53 （2021-02-01）
終値の最安値: $20.53 （2021-02-01）
Terns Pharmaceuticals, Inc. の株価履歴（2021 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -1.17% |
| 2025 | 517.55% |
| 2024 | -2.74% |
| 2023 | -12.48% |
| 2022 | 13.79% |
| 2021 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $525.30 | 23.23% |
US
|
|
| $252.60 | 818.88% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $888.91 | 6.49% |
NL
|
|
| $752.87 | 7.40% |
CH
|
